Evaluates amine oxide lipid nanoparticles for enhanced delivery of cyclic dinucleotides, suggesting improved cancer treatment effectiveness.
The clinical potential of cyclic dinucleotides (CDNs) as potent agonists of stimulator of interferon gene (STING) has been hampered by the lack of robust delivery systems. While lipid nanoparticles (LNPs) excel with large nucleic acids, they are unsuitable for delivering small, zwitterionic and highly hydrophilic CDNs. Here, we find that the tertiary amine oxide lipid (AOL) promotes stable encapsulation of CDNs into LNP through enhanced hydrogen bonding and electrostatic interactions, resulting in ultra-high encapsulation efficiency of 86.8%. Compared to cationic liposomes, AOL-incorporating LNP exhibits superior tumor penetration and cytosolic cargo delivery, eliciting broad and potent intratumoral STING activation. In line with growing emphasis on combination therapy in oncology, we further incorporate lipidated mitoxantrone in the LNP as an inducer of immunogenic cell death to enhance tumor antigen presentation and STING-driven immunotherapy. The obtained LNP provokes potent immunostimulatory and anti-tumor effects in multiple challenging animal models, including triple-negative breast cancer, pancreatic cancer and melanoma.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: